vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and Perimeter Solutions, Inc. (PRM). Click either name above to swap in a different company.

Perimeter Solutions, Inc. is the larger business by last-quarter revenue ($102.8M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 19.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $11.6M). Over the past eight quarters, Perimeter Solutions, Inc.'s revenue compounded faster (31.9% CAGR vs 31.3%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Perimeter 81 is an Israeli cloud and network security company that develops secure remote networks, based on the zero trust architecture, for organizations. Its technology replaces legacy security appliances like VPNs and firewalls.

PBYI vs PRM — Head-to-Head

Bigger by revenue
PRM
PRM
1.4× larger
PRM
$102.8M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+8.6% gap
PBYI
27.7%
19.2%
PRM
More free cash flow
PBYI
PBYI
$2.8M more FCF
PBYI
$14.4M
$11.6M
PRM
Faster 2-yr revenue CAGR
PRM
PRM
Annualised
PRM
31.9%
31.3%
PBYI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
PRM
PRM
Revenue
$75.5M
$102.8M
Net Profit
$-140.2M
Gross Margin
69.3%
45.2%
Operating Margin
22.7%
-160.7%
Net Margin
-136.5%
Revenue YoY
27.7%
19.2%
Net Profit YoY
-197.3%
EPS (diluted)
$0.26
$-0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
PRM
PRM
Q4 25
$75.5M
$102.8M
Q3 25
$54.5M
$315.4M
Q2 25
$52.4M
$162.6M
Q1 25
$46.0M
$72.0M
Q4 24
$59.1M
$86.2M
Q3 24
$80.5M
$288.4M
Q2 24
$47.1M
$127.3M
Q1 24
$43.8M
$59.0M
Net Profit
PBYI
PBYI
PRM
PRM
Q4 25
$-140.2M
Q3 25
$8.8M
$-90.7M
Q2 25
$5.9M
$-32.2M
Q1 25
$3.0M
$56.7M
Q4 24
$144.2M
Q3 24
$20.3M
$-89.2M
Q2 24
$-4.5M
$21.6M
Q1 24
$-4.8M
$-82.6M
Gross Margin
PBYI
PBYI
PRM
PRM
Q4 25
69.3%
45.2%
Q3 25
77.7%
63.1%
Q2 25
76.5%
62.4%
Q1 25
77.1%
39.1%
Q4 24
76.4%
48.6%
Q3 24
63.9%
62.8%
Q2 24
77.4%
57.6%
Q1 24
75.5%
35.1%
Operating Margin
PBYI
PBYI
PRM
PRM
Q4 25
22.7%
-160.7%
Q3 25
17.6%
-27.7%
Q2 25
12.7%
-16.1%
Q1 25
8.7%
Q4 24
22.6%
71.1%
Q3 24
27.4%
-12.2%
Q2 24
-4.6%
35.4%
Q1 24
-5.3%
-126.8%
Net Margin
PBYI
PBYI
PRM
PRM
Q4 25
-136.5%
Q3 25
16.2%
-28.7%
Q2 25
11.2%
-19.8%
Q1 25
6.5%
78.7%
Q4 24
167.2%
Q3 24
25.2%
-30.9%
Q2 24
-9.6%
17.0%
Q1 24
-11.0%
-139.8%
EPS (diluted)
PBYI
PBYI
PRM
PRM
Q4 25
$0.26
$-0.89
Q3 25
$0.17
$-0.62
Q2 25
$0.12
$-0.22
Q1 25
$0.06
$0.36
Q4 24
$0.40
$1.00
Q3 24
$0.41
$-0.61
Q2 24
$-0.09
$0.14
Q1 24
$-0.10
$-0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
PRM
PRM
Cash + ST InvestmentsLiquidity on hand
$97.5M
$325.9M
Total DebtLower is stronger
$22.7M
$669.1M
Stockholders' EquityBook value
$130.3M
$1.1B
Total Assets
$216.3M
$2.7B
Debt / EquityLower = less leverage
0.17×
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
PRM
PRM
Q4 25
$97.5M
$325.9M
Q3 25
$94.4M
$340.6M
Q2 25
$96.0M
$140.7M
Q1 25
$93.2M
$200.1M
Q4 24
$101.0M
$198.5M
Q3 24
$96.7M
$223.1M
Q2 24
$96.8M
$43.2M
Q1 24
$107.2M
$38.7M
Total Debt
PBYI
PBYI
PRM
PRM
Q4 25
$22.7M
$669.1M
Q3 25
$34.0M
$668.8M
Q2 25
$45.3M
$668.4M
Q1 25
$56.7M
$668.1M
Q4 24
$68.0M
$667.8M
Q3 24
$79.3M
$667.4M
Q2 24
$90.7M
$667.1M
Q1 24
$102.0M
$666.8M
Stockholders' Equity
PBYI
PBYI
PRM
PRM
Q4 25
$130.3M
$1.1B
Q3 25
$115.3M
$1.1B
Q2 25
$104.7M
$1.2B
Q1 25
$97.1M
$1.2B
Q4 24
$92.1M
$1.2B
Q3 24
$71.1M
$1.0B
Q2 24
$48.5M
$1.1B
Q1 24
$51.0M
$1.1B
Total Assets
PBYI
PBYI
PRM
PRM
Q4 25
$216.3M
$2.7B
Q3 25
$202.9M
$2.6B
Q2 25
$194.9M
$2.5B
Q1 25
$196.2M
$2.4B
Q4 24
$213.3M
$2.4B
Q3 24
$220.7M
$2.5B
Q2 24
$205.0M
$2.3B
Q1 24
$214.1M
$2.3B
Debt / Equity
PBYI
PBYI
PRM
PRM
Q4 25
0.17×
0.59×
Q3 25
0.30×
0.60×
Q2 25
0.43×
0.57×
Q1 25
0.58×
0.55×
Q4 24
0.74×
0.58×
Q3 24
1.12×
0.67×
Q2 24
1.87×
0.62×
Q1 24
2.00×
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
PRM
PRM
Operating Cash FlowLast quarter
$14.4M
$18.6M
Free Cash FlowOCF − Capex
$14.4M
$11.6M
FCF MarginFCF / Revenue
19.1%
11.3%
Capex IntensityCapex / Revenue
0.0%
6.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$208.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
PRM
PRM
Q4 25
$14.4M
$18.6M
Q3 25
$9.7M
$198.7M
Q2 25
$14.1M
$-2.9M
Q1 25
$3.6M
$23.7M
Q4 24
$15.6M
$-6.0M
Q3 24
$11.0M
$183.0M
Q2 24
$1.0M
$8.6M
Q1 24
$11.2M
$2.8M
Free Cash Flow
PBYI
PBYI
PRM
PRM
Q4 25
$14.4M
$11.6M
Q3 25
$9.7M
$193.6M
Q2 25
$14.1M
$-15.6M
Q1 25
$3.6M
$18.9M
Q4 24
$15.6M
$-12.4M
Q3 24
$11.0M
$179.1M
Q2 24
$1.0M
$5.0M
Q1 24
$1.2M
FCF Margin
PBYI
PBYI
PRM
PRM
Q4 25
19.1%
11.3%
Q3 25
17.7%
61.4%
Q2 25
26.8%
-9.6%
Q1 25
7.7%
26.3%
Q4 24
26.4%
-14.4%
Q3 24
13.7%
62.1%
Q2 24
2.1%
3.9%
Q1 24
2.1%
Capex Intensity
PBYI
PBYI
PRM
PRM
Q4 25
0.0%
6.8%
Q3 25
0.0%
1.6%
Q2 25
0.0%
7.8%
Q1 25
0.1%
6.7%
Q4 24
0.0%
7.5%
Q3 24
0.0%
1.3%
Q2 24
0.0%
2.9%
Q1 24
0.0%
2.6%
Cash Conversion
PBYI
PBYI
PRM
PRM
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
0.42×
Q4 24
-0.04×
Q3 24
0.54×
Q2 24
0.40×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PBYI
PBYI

Segment breakdown not available.

PRM
PRM

Products$87.7M85%
Service And Other$14.8M14%

Related Comparisons